A Phase 2 interventional study of OPC-41061 in Carcinomatous Edema, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-18.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
OPC-41061 will be administered to patients with volume overload associated with cancer, first by dose-escalation and subsequently for 6 consecutive days at the fixed dose at which urine volume is increased to investigate efficacy, pharmacokinetics, pharmacodynamic effects, and safety and to determine the effective initial and maintenance doses of OPC-41061.
568 studies on the registry are indexed under Edema; 97 are open to participants now.
This study's enrollment of 43 is below the median of 53 across 402 interventional studies indexed under Edema.
Browse Edema studies →Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with any of the following complications or symptoms:
Subjects with any of the following medical histories:
count of \< 75,000/mm3, of \< 8.0 g/dL, of \< 1,000/mm3, total of > 4.0 g/dL, serum creatinine of > 3.0 mg/dL, serum sodium of > 147 mEq/L, or serum potassium of > 5.5 mEq/L
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-41061
orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
Change in Body Weight From Baseline at Final IMP Administration
Body weight was measured in 100-g units before breakfast and after subjects had urinated at least once, taking care to minimize fluctuations due to defecation or clothing.
Time frame: Baseline, at the final IMP administration (shortest:7days longest:12days)
Change in Ascites Volume From Baseline Measured by Computer Tomography (CT) at Final IMP Administration
Time frame: Baseline, at the final IMP administration (shortest:7days longest:12days)
| Milestone | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| Started | 15 | 8 | 9 | 11 |
| Completed | 14 | 7 | 9 | 11 |
| Not completed | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| Started | 14 | 7 | 9 | 11 |
| Completed | 13 | 4 | 8 | 10 |
| Not completed | 1 | 3 | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
Body weight was measured in 100-g units before breakfast and after subjects had urinated at least once, taking care to minimize fluctuations due to defecation or clothing.
| Kg | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| Change in Body Weight From Baseline at Final IMP Administration | -0.69 ± 2.51 | -0.34 ± 1.99 | -1.13 ± 1.62 | 0.70 ± 1.56 |
| mL | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| Change in Ascites Volume From Baseline Measured by Computer Tomography (CT) at Final IMP Administration | -77.20 ± 982.19 | 513.97 ± 653.30 | 153.72 ± 993.63 | 539.93 ± 659.36 |
Collected over Treatment-emergent adverse events (TEAEs) were collected from the start of IMP administration up to 10 days after the final IMP administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OPC-41061 3.75 mg | 0/15 (0%) | 1/15 (6.7%) | 8/15 (53.3%) |
| OPC-41061 7.5 mg | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| OPC-41061 15 mg | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| OPC-41061 30 mg | 0/11 (0%) | 0/11 (0%) | 10/11 (90.9%) |
| Event | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/15 | 0/8 | 0/9 | 0/11 |
| Event | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 2/15 | 0/8 | 2/9 | 1/11 |
| ConstipationGastrointestinal disorders | 0/15 | 1/8 | 0/9 | 2/11 |
| NauseaGastrointestinal disorders | 0/15 | 0/8 | 0/9 | 2/11 |
| Renal impairmentRenal and urinary disorders | 0/15 | 0/8 | 1/9 | 2/11 |
| LeukopeniaBlood and lymphatic system disorders | 0/15 | 1/8 | 0/9 | 0/11 |
| NeutropeniaBlood and lymphatic system disorders | 0/15 | 1/8 | 1/9 | 0/11 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/15 | 1/8 | 0/9 | 0/11 |
| NasopharyngitisInfections and infestations | 0/15 | 1/8 | 0/9 | 0/11 |
| Blood osmolarity increasedInvestigations | 1/15 | 1/8 | 0/9 | 1/11 |
| Bile duct cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 1/8 | 0/9 | 0/11 |
Full analysis set: all subjects who had been administered the investigational medicinal product (IMP) at least once and from whom data for efficacy endpoints were obtained after the start of IMP administration.
| Age, Continuous(years) | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 63.3 ± 9.9 | 66.1 ± 8.5 | 62.2 ± 7.6 | 69.5 ± 7.9 | 65.3 ± 8.8 |
| Sex: Female, Male(Participants) | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg | Total |
|---|---|---|---|---|---|
| Female | 6 | 4 | 7 | 7 | 24 |
| Male | 7 | 3 | 2 | 4 | 16 |
| Race/Ethnicity, Customized(Participants) | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg | Total |
|---|---|---|---|---|---|
| Japanese | 13 | 7 | 9 | 11 | 40 |
| Region of Enrollment(Participants) | OPC-41061 3.75 mg | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg | Total |
|---|---|---|---|---|---|
| Japan | 13 | 7 | 9 | 11 | 40 |
The record gives a start of Jul 2012, a primary completion of Dec 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2021, 7 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Co., Ltd. →